医学
转移性乳腺癌
肿瘤科
曲妥珠单抗
内科学
乳腺癌
队列研究
回顾性队列研究
队列
期限(时间)
总体生存率
癌症
基于人群的研究
化疗
作者
Jean‐Philippe Spano,Philippe Beuzeboc,David Coeffic,Laurent Arnould,Alain Lortholary,Fabrice André,Jean‐Marc Ferrero
出处
期刊:The Breast
[Elsevier BV]
日期:2015-04-25
卷期号:24 (4): 376-383
被引量:18
标识
DOI:10.1016/j.breast.2015.02.035
摘要
The LORHA study showed that long term responders to 1st-line trastuzumab for locally advanced or metastatic breast cancer could achieve a median PFS of more than 6 years, with an acceptable safety profile.
科研通智能强力驱动
Strongly Powered by AbleSci AI